Enfuvirtide (Fuzeon®): The first fusion inhibitorWILLIAMS, I. G.International journal of clinical practice (Esher). 2003, Vol 57, Num 10, pp 890-897, issn 1368-5031, 8 p.Article

Resistance to enfuvirtide, the first HIV fusion inhibitorGREENBERG, Michael L; CAMMACK, Nick.Journal of antimicrobial chemotherapy (Print). 2004, Vol 54, Num 2, pp 333-340, issn 0305-7453, 8 p.Article

An Open-Label Safety Study of Enfuvirtide Injection with a Needle-Free Injection Device or Needle/Syringe : The Biojector 2000 Open-Label Safety Study (BOSS)LALEZARI, Jacob P; SAAG, Michael; WALWORTH, Charles et al.AIDS research and human retroviruses. 2008, Vol 24, Num 6, pp 805-813, issn 0889-2229, 9 p.Article

Adherence to Enfuvirtide and Its Impact on Treatment EfficacyROCKSTROH, Jürgen; DEJESUS, Edwin; THOMMES, James et al.AIDS research and human retroviruses. 2008, Vol 24, Num 2, pp 141-148, issn 0889-2229, 8 p.Article

Enfuvirtide: A fusion inhibitor for the treatment of HIV infectionFUNG, Horatio B; YI GUO.Clinical therapeutics. 2004, Vol 26, Num 3, pp 352-378, issn 0149-2918, 27 p.Article

A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtideMYERS, Sarah A; SELIM, Angelica A; MCDANIEL, Margaret A et al.Antiviral therapy (London). 2006, Vol 11, Num 7, pp 935-939, issn 1359-6535, 5 p.Article

Short Communication: Evaluation of the Effect of Enfuvirtide in 11 HIV-1 Vertically Infected Pediatric Patients Outside Clinical TrialsPALLADINO, C; BRIZ, V; GONZALEZ-TOME, M. I et al.AIDS research and human retroviruses. 2010, Vol 26, Num 3, pp 301-305, issn 0889-2229, 5 p.Article

A Report on the Effect of Commencing Enfuvirtide on Peripheral NeuropathyCHERRY, Catherine L; DUNCAN, Alison J; MACKIE, Kathryn F et al.AIDS research and human retroviruses. 2008, Vol 24, Num 8, pp 1027-1030, issn 0889-2229, 4 p.Article

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settingsSTOCKER, Hartmut; KLOFT, Charlotte; ROELING, Joerg et al.Antimicrobial agents and chemotherapy. 2006, Vol 50, Num 2, pp 667-673, issn 0066-4804, 7 p.Article

Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 diseaseKITCHEN, Christina M. R; JING LU; SUCHARD, Marc A et al.AIDS research and human retroviruses. 2006, Vol 22, Num 12, pp 1260-1266, issn 0889-2229, 7 p.Article

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimenLALEZARI, Jacob P; BELLOS, Nicholaos C; YING ZHANG et al.The Journal of infectious diseases. 2005, Vol 191, Num 7, pp 1155-1163, issn 0022-1899, 9 p.Article

Interruption of enfuvirtide in HIV-1-infected adults with incomplete viral suppression on an enfuvirtide-based regimen. CommentaryMORSE, Caryn; MALDARELLI, Frank; MARTIN, Jeffrey N et al.The Journal of infectious diseases. 2007, Vol 195, Num 3, issn 0022-1899, 318-321,387-391 [9 p.]Article

Cutaneous injection site reactions to long-term therapy with enfuvirtideMAGGI, Paolo; LADISA, Nicoletta; CINORI, Eliana et al.Journal of antimicrobial chemotherapy (Print). 2004, Vol 53, Num 4, pp 678-681, issn 0305-7453, 4 p.Article

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtideWALMSLEY, Sharon; HENRY, Keith; DELEHANTY, John et al.The Journal of infectious diseases. 2003, Vol 188, Num 12, pp 1827-1833, issn 0022-1899, 7 p.Article

Switch From Enfuvirtide to Raltegravir in Patients With Undetectable Viral Load: Efficacy and Safety at 24 Weeks in a Montreal CohortTALBOT, Annie; MACHOUF, Nima; THOMAS, Réjean et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 3, pp 362-364, issn 1525-4135, 3 p.Article

First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three casesBOURGARIT, Anne; LASCOUX, Caroline; PALMER, Pierre et al.AIDS (London). 2006, Vol 20, Num 3, pp 471-473, issn 0269-9370, 3 p.Article

Successful desensitization of enfuvirtide after a first attempt failureMACHADO, Elizabeth S; PASSONI, Luis Fernando C; SIDI, Leon Claude et al.AIDS (London). 2006, Vol 20, Num 16, pp 2130-2131, issn 0269-9370, 2 p.Article

Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypesCOVENS, Kris; KABEYA, Kabamba; SCHROOTEN, Yoeri et al.Journal of clinical virology. 2009, Vol 44, Num 4, pp 325-328, issn 1386-6532, 4 p.Article

Unexpected Dramatic Increase in CD4⁺ Cell Count in a Patient With AIDS After Enfuvirtide Treatment Despite Persistent Viremia and Resistance MutationsSORIA, Alessandro; CAVARELLI, Mariangela; SALA, Stefania et al.Journal of medical virology. 2008, Vol 80, Num 6, pp 937-941, issn 0146-6615, 5 p.Article

Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapyPOVEDA, Eva; RODES, Berta; LEBEL-BINAY, Sophie et al.Journal of clinical virology. 2005, Vol 34, Num 4, pp 295-301, issn 1386-6532, 7 p.Article

Immunologic Benefits of Enfuvirtide in Patients Enrolled in a Drug Assistance ProgramSABERI, Parya; CASWELL, Nikolai H; GRUTA, Cristina I et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 5, pp 621-626, issn 1060-0280, 6 p.Article

Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivoTRABAUD, Mary Anne; COTTE, Laurent; LABERNARDIERE, Jean Louis et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 46, Num 2, pp 134-144, issn 1525-4135, 11 p.Article

Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjectsTHOMPSON, Melanie; DEJESUS, Edwin; MIRALLES, G. Diego et al.AIDS (London). 2006, Vol 20, Num 3, pp 397-404, issn 0269-9370, 8 p.Article

Rapid emergence of enfuvirtide resistance in HIV-1-infected patients : Results of a clonal analysisJING LU; DEEKS, Steven G; HOH, Rebecca et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 1, pp 60-64, issn 1525-4135, 5 p.Article

Enfuvirtide resistance mutations : Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralizationREEVES, Jacqueline D; LEE, Fang-Hua; MIAMIDIAN, John L et al.Journal of virology. 2005, Vol 79, Num 8, pp 4991-4999, issn 0022-538X, 9 p.Article